4010-81-5

Basic information

• Product Name: 2-chloro-6-(morpholin-4-yl)-5H-purine
• CAS NO: 4010-81-5
• Molecular Formula: C₉H₁₀ClN₅O
• Molecular Weight: 239.6616
• Mol File: 4010-81-5.mol
• Article Data: 26

Chemical Properties

• Boiling Point: 373.3°C at 760 mmHg
• Flash Point: 179.6°C
• Density: 1.74g/cm³
• Vapor Pressure: 9.06E-06mmHg at 25°C
• Refractive Index: 1.796
• CAS DataBase Reference: 2-chloro-6-(morpholin-4-yl)-5H-purine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-6-(morpholin-4-yl)-5H-purine(4010-81-5)
• EPA Substance Registry System: 2-chloro-6-(morpholin-4-yl)-5H-purine(4010-81-5)

Safety Data

• Hazardous Substances Data: 4010-81-5(Hazardous Substances Data)

Usage

General Description

2-Chloro-6-(morpholin-4-yl)-5H-purine, also known as compound CMPD000065278, is a chemical compound that belongs to the class of purine derivatives. It is a synthetic molecule with a purine core, where a morpholine group and a chlorine atom are attached to specific positions of the purine framework. 2-chloro-6-(morpholin-4-yl)-5H-purine has been studied for its potential pharmaceutical applications, particularly as a kinase inhibitor. It is also used as a chemical building block in the synthesis of other molecules. The structure of 2-Chloro-6-(morpholin-4-yl)-5H-purine makes it a promising candidate for further research and development in the field of medicinal chemistry.

Upstream product

• 110-91-8 morpholine 
• 5451-40-1 2,6-dichloro-7H-purine 
• 5451-40-1 2,6 dichloropurine 
• 5451-40-1 2,6-dichloropurine 
• 95758-04-6 2-chloro-6-(morpholin-4-yl)-9-(tetrahydro-2H-pyran-2-yl)-9H-purine 
• 149948-30-1 N-(6-chloro-9H-purin-2-yl)formamide 
• 73-40-5 2-amino-1,9-dihydro-6H-purin-6-one 
• 10310-21-1 2-Amino-6-chloropurin 

Downstream Products

• 7474-73-9 6-morpholino-2-piperidino-7(9)H-purine 
• 2846-96-0 6-morpholino-7⁽⁹⁾H-purine 
• 7471-61-6 (6-morpholino-7(9)H-purin-2-yl)-hydrazine 
• 7494-71-5 4,4'-(9H-purine-2,6-diyl)dimorpholine 
• 682337-90-2 [2-(3,4-dimethoxy-phenyl)-ethyl]-(6-morpholin-4-yl-9H-purin-2-yl)amine 
• 1062205-49-5 9-(1-benzyl-piperidin-4-yl)-2-chloro-6-morpholin-4-yl-9H-purine 
• 934545-07-0 3-[6-(4-morpholinyl)-9H-purin-2-yl]-phenol 
• 1148003-91-1 2-chloro-6-morpholin-4-yl-9-[2-(tetrahydropyran-2-yloxy)ethyl]-9H-purine 
• 1062203-86-4 [4-(6-morpholin-4-yl-9H-purin-2-yl)phenyl]methanol 
• 1062203-80-8 2-(6-morpholin-4-yl-9H-purin-2-yl)phenol 
• 1062203-83-1 4-(6-morpholin-4-yl-9H-purin-2-yl)phenol 
• 1062204-03-8 3-(6-morpholin-4-yl-9H-purin-2-yl)benzonitrile 
• 1062204-08-3 N-(3-(6-morpholino-9H-purin-2-yl)phenyl)methanesulfonamide 
• 1062204-17-4 2-[3-(methylsulfonyl)phenyl]-6-morpholin-4-yl-9H-purine 

Relevant articles and documents

High yielding, base catalyzed C6 regioselective amination and N9 alkylation in purine nucleotide

2,6-Dichloropurine is an interesting new nucleoside which gave regioselectively various 2-derivatized or 6-derivatized purines by using a secondary amines. An efficient, simple and regioselective synthesis of C6 morpholine, N9 alkylated purine nucleoside derivatives were attained via chloro-amine coupling reaction between 2,6-dichloropurine with morpholine followed by commercial alkylation method using DMF and K2CO3. Over the traditionally used protocols and procedure, it have been exhibited advance benefits such as admirable yield, simple reaction conditions and modest influence.

Piperazinone substitute or derivative thereof, preparation method and application thereof, and pharmaceutical composition

The invention relates to a piperazinone substitute or a derivative thereof, a preparation method and application thereof, and a pharmaceutical composition, and belongs to the technical field of anti-tumor drugs. The invention designs a piperazinone substituted heterocyclic small molecule compound. The compound shows good affinity to PI3K delta, and the compound can down-regulate the activity of a PI3K pathway in tumor cells, so that the compound shows good inhibitory activity to PI3K delta dependent tumors, and is expected to be used as one of components of a pharmaceutical preparation for treatment of different tumors. The preparation method of the piperazinone substitute is simple and convenient, and the yield is relatively high.

DUAL KINASE-BROMODOMAIN INHIBITORS

Provided herein are compounds of Formula (I) that are dual inhibitors of kinases and bromo-domain proteins. The disclosure also relates to pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of cancers, particularly, the treatment of multiple myeloma cancers, and to related uses.

Design, synthesis and biological evaluation of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent Kinase2 (CDK2) dual inhibitors against malignant cancer

In the current study, we have designed and synthesized a series of novel histone deacetylase1/2 (HDAC1/2) and cyclin-dependent kinase2 (CDK2) dual inhibitors by integrating purine-based pharmacophore into the recognition cap group of CS055. The representative compound 14d with excellent antiproliferative activities towards five solid cancer cells, showed potent inhibitory activities against HDAC1, HDAC2 and CDK2 with IC50 values of 70.7 nM, 23.1 nM and 0.80 μM, respectively. Besides, compound 14d could effectively block the cell cycle in the G2/M phase and induce apoptosis, which might be related to increasing intracellular ROS levels. Importantly, compound 14d exhibited desirable pharmacokinetic (PK) properties with the intraperitoneal bioavailability of 50.8percent in ICR mice, and potent in vivo antitumor activity in the HCT116 xenograft model. Therefore, compound 14d could be considered as a promising lead compound for the development of multitargeting anticancer agents.